You are here

Article Text

Article menu
Download PDFPDF
Letter
Rituximab therapy for refractory systemic-onset juvenile idiopathic arthritis
  1. J Narváez1,
  2. C Díaz-Torné2,
  3. X Juanola1,
  4. C Geli2,
  5. J M Llobet2,
  6. J M Nolla1,
  7. C Díaz-López2
  1. 1
    Department of Rheumatology, Hospital Universitario de Bellvitge–IDIBELL, Barcelona, Spain
  2. 2
    Department of Rheumatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
  1. Dr F J Narváez García, Department of Rheumatology (planta 10–2), Hospital Universitario de Bellvitge, Feixa Llarga s/n 08907, L’Hospitalet de Llobregat, Barcelona, Spain; 31577edd{at}comb.es

https://doi.org/10.1136/ard.2008.092106

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Systemic-onset juvenile idiopathic arthritis (SOJIA), formerly called Still’s disease, is a subset of juvenile arthritis that describes patients with fever, rash, arthritis, serositis and visceromegaly. In up to 30% of cases the disease has a chronic course and management requires high doses of glucocorticoids, disease-modifying antirheumatic drugs (DMARD), tumour necrosis factor alpha (TNFα) inhibitors or anakinra.1–6 However, this therapeutic arsenal is unable to control the disease in all patients.

    Recently, rituximab, a chimeric anti-CD20 monoclonal antibody, has been successfully used in two patients with refractory adult-onset Still’s disease.7 As the similarity of clinical and laboratory features present in SOJIA and adult-onset Still’s disease implies that these conditions have similar …

    View Full Text

    Footnotes

    • Competing interests: None.

    • Ethics approval: Ethics approval was obtained.

    • Patient consent: Obtained.